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The United States has been ex-periencing an increasing num-
ber of measles outbreaks, and 
more measles cases were reported 
in the first 5 months of 2019 than 
in any full year since 1992, which 
was 8 years before endemic trans-
mission was interrupted. Parents’ 
resistance to vaccination is leav-
ing more children vulnerable to 
measles and various other pre-
ventable illnesses. Some of these 
children have begun to seek op-
portunities to revisit vaccine- 
refusal decisions made on their 
behalf by their parents and are 
now pursuing vaccination.
In a March 2019 congressional 
hearing on preventable disease 
outbreaks, Ohio high school senior 
Ethan Lindenberger shared his ex-
perience of trying to get vaccinat-
ed over his mother’s objections. 
Lindenberger testified that his 
mother is an antivaccine advocate 
who believes that vaccines can 
cause autism and brain damage, 
“despite the fact such opinions 
have been debunked numerous 
times by the scientific commu-
nity.”1 Once he turned 18, Linden-
berger went to a public health 
clinic for vaccinations against 
hepatitis A and B, influenza, and 
human papillomavirus (HPV).
Such cases raise the question of 
whether adolescent minors should 
be able to consent to vaccinations 
without parental permission. For 
minors to be able to choose to be 
vaccinated over parental objections, 
most states would need to make 
substantive changes to laws govern-
ing medical consent. Since children 
are generally considered nonauto-
nomous under U.S. law, treatment 
of a child in a medical setting re-
quires parental permission, typical-
ly until a child reaches 18 years 
of age. Parents are generally given 
broad discretion in making deci-
sions on behalf of their children, 
in part because they know their 
child best, are positioned to weigh 
competing family interests, and 
are permitted to raise their child 
as they choose. Such discretion 
doesn’t mean that adolescents 
have no role in decisions that af-
fect them, however. Out of respect 
for adolescents’ developing auton-
omy, clinicians routinely explore 
their understanding of health-
related issues, solicit their agree-
ment on care plans, navigate dis-
cordance between parental and 
adolescent preferences, and pro-
tect adolescents’ confidentiality 
interests.2
Both ethical principles and state 
laws also support independent de-
cision making by adolescents in 
cases in which failing to grant 
adolescents autonomy could fore-
seeably result in substantial risk 
to the minor or to public health. 
For instance, all states have laws 
permitting minors to make inde-
pendent, confidential clinical de-
cisions regarding certain sensitive 
or stigmatized health care servic-
es, such as those related to sex-
ual health, reproduction, mental 
health, and substance use disor-
ders. Roughly 20% of jurisdictions 
require adolescents to be at least 
12 or 14 years of age to make 
such decisions; others don’t desig-
nate a minimum age of consent.3 
A court may also grant an older 
adolescent (typically 16 years or 
older) legal emancipation or deem 
the adolescent to be a “mature mi-
nor” who is able to make certain 
decisions independently.
Most states, however, don’t au-
thorize adolescents to indepen-
dently consent to vaccination. 
Under consent-related rules for 
sensitive or stigmatized health 
care services, several jurisdictions, 
such as California and New York, 
allow adolescents to make deci-
sions regarding prevention of 
sexually transmitted infections 
(STIs), which includes acceptance 
of hepatitis B and HPV vaccines 
(see table).3 Idaho allows adoles-
cents to make independent medi-
cal decisions when a clinician be-
lieves the minor is capable of 
fulfilling informed-consent re-
sponsibilities. At least three other 
states permit adolescents to make 
a broad array of autonomous clin-
ical decisions, including regard-
ing vaccination (Alabama at 14 
years of age, Oregon at 15, and 
South Carolina at 16). Alaska 
 allows minors to make indepen-
dent decisions when a parent “is 
unwilling either to grant or with-
hold consent.”
Bills have been proposed in at 
least two jurisdictions in 2019 to 
grant adolescents independent au-
thority to consent to vaccination. 
New York’s bill would allow any-
one 14 or older to consent to any 
vaccine required for school or 
day care entry (measles–mumps–
rubella, diphtheria, tetanus, per-
tussis, poliomyelitis, hepatitis B, 
varicella, and meningitis vaccines). 
A bill in Washington, D.C., would 
permit any minor deemed by a 
clinician to be capable of meet-
ing informed-consent standards 
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for care to consent to any vaccine 
recommended by the Advisory 
Committee on Immunization 
Practices, which includes HPV 
and annual influenza vaccines 
along with those covered in New 
York’s bill.
Granting adolescents the au-
thority to agree to vaccination 
without parental permission would 
allow them to catch up on any 
missed childhood vaccines. Al-
though not a panacea for all vac-
cine uptake and access problems, 
such laws could improve rates of 
vaccination against highly infec-
tious diseases such as measles. 
They may be particularly relevant 
for vaccines recommended for 
adolescents owing to the lack of 
regular preventive care visits 
among this group.4 Adolescents 
could receive vaccines in alterna-
tive settings, such as pharmacies, 
which may be more accessible 
than health care offices in rural 
areas, or school health clinics. 
Consent requirements can also 
be a barrier to vaccination in alter-
native settings, however. For in-
stance, some state laws constrain 
pharmacists from vaccinating pa-
tients younger than 18, and some 
schools require consent from 
parents to vaccinate children.
If minors are authorized to 
consent to vaccination, at what 
age should this right be granted? 
Although a broad guideline def-
erential to clinical judgment, as is 
outlined in the bill being consid-
ered in Washington, D.C., offers 
maximal flexibility, it also seems 
prudent to link consent to vacci-
nation to a specific age at which 
minors are already granted deci-
sion-making authority. This cut-
off could be as early as 12, in 
keeping with the age at which 
many states grant minors deci-
sion-making authority for STI-
related services, or 14, as it is 
under Alabama’s broader law on 
clinical decision making. Setting 
an explicit age would provide a 
more just and clear implementa-
tion standard for all adolescents 
and the clinicians treating them. 
On average, professionals respond-
ing to a recent survey reported 
that they were comfortable with 
patients at least 14 years of age 
consenting to vaccines recom-
mended for adolescents, including 
vaccines against pertussis, menin-
gitis, HPV, and influenza.5
State Bill or Law (Citation) Minimum Age
Consent to  
STI-Related  
Vaccines  
Only
Consent to  
Any  
Required  
Vaccines
Consent to  
Any ACIP- 
Recommended 
Vaccines
Consent to Any 
Health Care,  
Including  
Vaccination
New York Bill (A06564) 14 yr X
District of 
Columbia
Bill (B23-0171) None, as long as minor  
is capable of meeting  
informed-consent  standards
X
California Law (CA Family Code 6926) 12 yr X 
Delaware Law (Del. Code Ann. tit. 13, 
§ 710)
12 yr X 
District of 
Columbia
Law (D.C. Mun. Regs. tit. 22, 
§ 600.7)
None X 
Minnesota Law (Minn. Stat. § 144.3441) None  X†
New York Law (NY Consol. Laws PBH 
§ 2305, 10 NYCRR 23.4)
None X 
Alaska Law (AS 25.20.025) None, when parent or guard-
ian “is unwilling either to 
grant or withhold consent”
X
Idaho Law (ID Code 39-4503) None, as long as minor  
is capable of meeting  
informed-consent  standards
X
Alabama Law (AL Code 22-8-4) 14 yr X
Oregon Law (2017 ORS 109.640) 15 yr X
South Carolina Law (SC 63-5-340) 16 yr X
*  Abortion-related care is not included under Alaska’s law. Under South Carolina’s law, no consent other than the minor’s is needed unless 
 providers believe proposed health services are “essential to the health or life of (the) child.” ACIP denotes the Advisory Committee on 
Immunization Practices, and STI sexually transmitted infection.
†  Hepatitis B only.
Statutes and Bills Regarding Adolescents’ Consent to Treatment.*
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Granting minors decision-mak-
ing authority for vaccination also 
triggers reconsideration of the 
materials and associated commu-
nication needed to ensure that 
they can make informed decisions. 
Federal law requires that clini-
cians provide adult patients and 
children’s parents or legal repre-
sentatives with a Vaccine Infor-
mation Sheet before vaccination. 
Since such materials are written 
at a 10th-grade reading level, they 
would most likely require revision 
if intended recipients were to in-
clude adolescents as young as 12 
or 14 years of age.
Parental involvement in vac-
cination decisions remains im-
portant. Many vaccine-hesitant 
parents ultimately agree to vac-
cination. Yet adolescents need not 
be harmed by parental decisions 
that are based on misinforma-
tion or disinformation. Allowing 
adolescents to consent to vacci-
nation despite persistent parental 
resistance facilitates access to a 
medically recommended and evi-
dence-based treatment. It pro-
motes the minor’s health, poses 
minimal personal risk, and offers 
substantial prosocial benefits, in-
cluding reinforcement of the norm 
of vaccination and enhancement 
of community protection against 
the spread of dangerous and 
costly yet preventable diseases. 
Given such benefits, we believe 
that states should enact laws that 
expand both access to vaccines 
and the rights of minors who are 
at least 12 to 14 years of age to 
consent to vaccination.
Disclosure forms provided by the authors 
are available at NEJM.org.
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Congress passed the Orphan Drug Act in 1983 to spur de-
velopment of drugs to treat rare 
diseases. Among the law’s incen-
tives were exclusive marketing 
rights for 7 years for the rare-
disease indication (“orphan drug 
exclusivity”), a 50% tax credit for 
costs associated with the clinical 
testing of such drugs (reduced to 
25% in 2017), and grants for 
clinical trials. There has since 
been a marked increase in the 
number of drugs approved by the 
Food and Drug Administration 
(FDA) for rare diseases. Between 
1983 and 2017, a total of 487 
orphan-designated drugs entered 
the U.S. market.1 In 2018, of the 
new drugs approved, 58% (34 of 
59) were for a rare-disease indi-
cation.
At the same time, there has 
been growing concern that the 
Orphan Drug Act has been sub-
ject to gaming. The most recent 
controversy occurred in Decem-
ber 2018, when Catalyst Pharma-
ceuticals announced that it would 
price amifampridine (Firdapse), a 
treatment for the rare neuromus-
cular disease Lambert–Eaton my-
asthenic syndrome, at $375,000 
per year. Although the FDA had 
approved Catalyst’s product as an 
orphan-designated drug in No-
vember 2018, amifampridine was 
not new. It had been marketed in 
the United Kingdom since 2010 
at an annual price of less than 
£30,000 (about $40,000) per pa-
tient and was available to U.S. 
patients with the syndrome for 
free under an expanded-access 
program. In February 2019, Sena-
tor Bernie Sanders (I-VT) brought 
attention to this case and asked 
Catalyst to explain its pricing de-
cision. The company responded 
in part by arguing that amifam-
pridine’s price is in line with that 
of other products used to treat 
rare, severe diseases.
In recent years, several manu-
facturers have earned hundreds 
of millions of dollars in annual 
revenue from rare-disease drugs. 
The cystic fibrosis treatment luma-
caftor–ivacaftor (Orkambi), the 
idiopathic pulmonary fibrosis 
treatment pirfenidone (Esbriet), 
and the spinal muscular atrophy 
treatment nusinersen (Spinraza) 
each generated more than $1 bil-
lion in sales in 2018. Such cases 
raise the question of whether the 
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